Nonhuman Primate Reagent Resource

非人类灵长类动物试剂资源

• 批准号: 9312774
• 负责人: KEITH A. REIMANN
• 金额: $ 176.9万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-29 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9312774
• 关键词: Animal Model; Antibodies; Autoimmune Diseases; Biological Response Modifier Therapy; Budgets; Communicable Diseases; Communities; Data; Databases; Development; Diagnostic; Discipline; Disease; Disease model; Engineering; Formulation; Health Services Accessibility; Human; Immunologics; In Vitro; Lymphocyte Subset; Modeling; Organ Transplantation; Pathogenesis; Primates; Production; Quality Control; Reagent; Recombinant Antibody; Records; Research; Research Personnel; Resources; Role; Scientific Advances and Accomplishments; Testing; Therapeutic; Translational Research; United States National Institutes of Health; Vaccines; expression vector; immune function; in vivo; large scale production; nonhuman primate; novel therapeutics; outreach; programs; response; tool; web site

Nonhuman primates (NHPs) serve a crucial role in translational research as animal models for exploring the pathogenesis of infectious and noninfectious diseases, and for testing of biologic therapies and vaccines. While many human diagnostic immunologic reagents cross react with the primate species commonly employed in translational research, gaps exist for a substantial number of reagent targets. Furthermore, antibodies that target specific immune functions or deplete specific lymphocyte subpopulations in vivo have proven valuable in defining disease mechanisms or can be used as proof-of-concept for new therapies. For the past 15 years, the NIH Nonhuman Primate Reagent Resource has responded to needs of the scientific community by developing, manufacturing and distributing NHP- specific reagents for in vitro diagnostics and for in vivo use. Utilization of this resource has grown dramatically since this program's inception. During the last budget year, we fulfilled 500 reagent requests from 126 investigators and distributed over 300 grams of recombinant antibody for administration to NHPs. Taking advantage of scientific advances and technological improvements in antibody development, engineering, expression and vectoring, we will continue to support the scientific community utilizing NHP models across all scientific disciplines.

非人灵长类动物作为动物模型在转化研究中起着至关重要的作用 用于探索感染性和非感染性疾病的发病机理，以及用于检测 生物疗法和疫苗。虽然许多人类诊断免疫试剂 与转化研究中常用的灵长类物种反应， 大量的试剂靶。此外，靶向特异性免疫的抗体 功能或消耗体内特定的淋巴细胞亚群已被证明在 定义疾病机制或可用作新疗法的概念验证。 在过去的15年里，NIH非人灵长类动物试剂资源已经响应了 通过开发、制造和销售NHP，满足科学界的需求， 用于体外诊断和体内使用的特定试剂。利用这一资源， 在这个项目开始后急剧增长在上一个预算年度，我们实现了 126名调查员提出500份试剂申请，分发了300多克重组体 用于施用至NHP的抗体。 利用抗体领域的科学进步和技术进步 开发、工程、表达和矢量化，我们将继续支持 科学界在所有科学学科中使用NHP模型。